KAND 567

Drug Profile

KAND 567

Alternative Names: AZD-8797; KAN-0440567; KAND567

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Kancera
  • Class Analgesics; Antineoplastics; Small molecules
  • Mechanism of Action Chemokine CXCL13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders; Cancer; Cancer pain
  • Preclinical Breast cancer; Pancreatic cancer
  • Discontinued Multiple myeloma

Most Recent Events

  • 14 Sep 2017 Kancera enters into development and manufacturing agreement with Racipharm for KAND 567 in the treatment of Cancer pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top